If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Forsteo Summary of Product Characteristics (SmPC)
Forsteo® (teriparatide): Use in Patients with Myeloma
Use of Forsteo in patients with multiple myeloma is not approved.
Detailed
Information
Patients
with skeletal malignancies or bone metastases should be excluded from
treatment with teriparatide (contraindication).1
Osteoporosis
or pathological fracture may be one of the first signs of multiple
myeloma. Rapidly declining bone mineral density or low trauma
pathological fracture may warrant further evaluation, including
testing for monoclonal gammopathy.2
References
1.
Forsteo [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com